Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Flupirtine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 9/20 | 0.98 |
| ▸ | KCNQ3 known ✓ | O43525 | 7/20 | 0.98 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | KCNQ4 known ✓ | P56696 | 6/20 | 0.64 |
| ▸ | KCNQ5 known ✓ | Q9NR82 | 5/20 | 0.64 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flupirtine SCHEMBL29400613 | 0.99 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL3896230 | 0.99 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL25009 | 0.99 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL15357226 | 0.99 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505535 | 0.98 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL28262990 | 0.98 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505446 | 0.97 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505680 | 0.97 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL1649863 | 0.97 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505911 | 0.96 | KCNQ2 (0.94) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109806233-B | Composition containing flupirtine or medicinal salt thereof and preparation method thereof | 北京泰德制药股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-109053563-B | Method for preparing flupirtine hydrochloride | 四川青木制药有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-109806233-A | A kind of composition and preparation method thereof containing Flupirtine or its pharmaceutical salts | 北京泰德制药股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| US-20110275679-A1 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL | BIONEVIA PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2361247-A2 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL | Bionevia Pharmaceuticals Inc. (US) | 2011-08-31 | — | — | EP | claimed |
| WO-2010017343-A2 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| CN-119585256-A | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119528909-A | Bisheterocyclic derivative for inhibiting WRN helicase, pharmaceutical composition containing bisheterocyclic derivative and application of bisheterocyclic derivative | 上海科恩泰生物医药科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119365493-A | Anti-CD 84 antibodies and uses thereof | 希望之城公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-113425697-B | Preparation and preliminary pharmaceutical evaluation method of compound qi-tonifying intestine-moistening capsule | 山东中医药大学 | 2023-06-16 | — | — | CN | disclosed |
| CN-116171276-A | 3- ((1H-pyrazol-4-yl) methyl) -6'- (phenyl) -2H- [1,2' -bipyridin ] -2-one derivatives and related compounds as GRP139 antagonists in methods of treating E.G. depression | 武田药品工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| CN-109806233-B | Composition containing flupirtine or medicinal salt thereof and preparation method thereof | 北京泰德制药股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| CN-109053563-B | Method for preparing flupirtine hydrochloride | 四川青木制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-0160865-B1 | 2-AMINO-3-ETHOXYCARBONYLAMINO-6-(P-FLUORO-BENZYLAMINO)-PYRIDINE-GLUCONATE AND PHARMACEUTICAL COMPOUNDS CONTAINING THIS PRODUCT | Degussa Aktiengesellschaft (DE) | 1988-04-20 | — | — | EP | disclosed |
| US-4673666-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
| EP-0110091-B1 | DERIVATIVES OF 2-AMINO-3-ACYLAMINO-6-BENZYLAMINO PYRIDINE WITH AN ANTI-EPILEPTIC ACTIVITY | Degussa Aktiengesellschaft (DE) | 1987-01-21 | — | — | EP | disclosed |
| US-4554281-A | 2-Amino-3-acylamino-6-benzylamino-pyridine-derivative having antiepileptic action | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-11-19 | — | — | US | disclosed |
| EP-0160865-A2 | 2-Amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine-gluconate and pharmaceutical compounds containing this product | Degussa Aktiengesellschaft (DE) | 1985-11-13 | — | — | EP | disclosed |
| US-4481205-A | ANTIPHLOGISTIC, ANALGESIC | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-11-06 | — | — | US | disclosed |
| EP-0110091-A1 | Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity | Degussa Aktiengesellschaft (DE) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275679-A1 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL | MC2R, MC5R, HTR5A | KCNQ2 1274/4885KCNQ3 1428/4885ESR1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.